NCT06117137View on ClinicalTrials.gov

The Impact Of SGLT2 -I on Metabolic Dysfunction -Associated Steatotic Liver Disease In Patients With Type 2 Diabetes Mellitus

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

150

Participants

Timeline

Start Date

November 15, 2023

Primary Completion Date

October 31, 2024

Study Completion Date

October 31, 2024

Conditions

Fatty Liver, Nonalcoholic

Interventions

DRUG

SGLT2 inhibitor

"Group empagliflozin: stander treatment of type two diabetes mellitus plus empagliflozin~Group dapa:standard treatment of type 2 Diabetes mellitus and dapagliflozin"

All Listed Sponsors

lead

Sohag University

OTHER